Board Changes Ahead of Aclaris Therapeutics Annual Meeting
PremiumCompany AnnouncementsBoard Changes Ahead of Aclaris Therapeutics Annual Meeting
4M ago
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
PremiumPress Releases
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
5M ago
Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
PremiumThe Fly
Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
5M ago
Aclaris Therapeutics CEO Douglas Manion to step down
PremiumThe FlyAclaris Therapeutics CEO Douglas Manion to step down
6M ago
Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
PremiumThe Fly
Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
7M ago
Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
PremiumThe Fly
Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
7M ago
Aclaris Therapeutics Provides Corporate Update
PremiumPress ReleasesAclaris Therapeutics Provides Corporate Update
7M ago
Aclaris in alopecia patent license pact with Sun Pharma includes $15M upfront
PremiumThe Fly
Aclaris in alopecia patent license pact with Sun Pharma includes $15M upfront
8M ago
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
PremiumPress Releases
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100